Details for Patent: 8,632,787

Title:	Methods using immunomodulatory compounds for treatment of certain leukemias
Abstract:	Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Dec 02, 2011
Application Number:	13/310,543
Claims:	1. A method of treating a patient having acute myeloid leukemia, which comprises (a) administering to said patient a therapeutically effective amount of cytarabine and from about 5 mg per day to about 25 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione having the formula: ##STR00009## or a pharmaceutically acceptable salt, or solvate thereof wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered for 21 days followed by a period of rest; and (b) repeating step (a). 2. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 5 mg per day. 3. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 10 mg per day. 4. The method according to claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 15 mg per day. 5. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 25 mg per day. 6. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered orally. 7. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered as a free base. 8. The method of claim 1, wherein the cytarabine is administered subcutaneously or intravenously. 9. The method of claim 1, wherein the cytarabine is administered once or twice daily in an amount of from about 10 to about 375 mg. 10. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered cyclically in a four or six week cycle. 11. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered orally in an amount of about 10 mg per day for twenty-one days followed by a period of time of rest of each cycle. 12. The method of claim 1, wherein the cytarabine and the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or the pharmaceutically acceptable salt, solvate or stereoisomer thereof are administered concurrently. 13. The method of claim 1, wherein the cytarabine and the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or the pharmaceutically acceptable salt, solvate or stereoisomer thereof are administered sequentially.